The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.

The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.

The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.

Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.

One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.

Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.